Culture minister tours Saudi pavilion at Expo 2025 Osaka    Al Ahli edges Al Ain 2-1, bolsters perfect start in AFC Champions League Elite    Saud Abdulhamid makes history as first Saudi player in Serie A    Saudi Cabinet to hold special budget session on Tuesday    King Salman orders extension of Citizen's Account Program and additional support for a full year    Al-Falih: 1,238 foreign investors obtain premium residency in Saudi Arabia    Irish PM apologizes for walking away from care worker    Several dead as Storm Bert wreaks havoc across Britain    Most decorated Australian Olympian McKeon retires    Adele doesn't know when she'll perform again after tearful Vegas goodbye    'Pregnant' for 15 months: Inside the 'miracle' pregnancy scam    Ukraine losing ground in Russia's Kursk region, says military source    Hezbollah fires rocket barrages into Israel after deadly Beirut strikes    Al Ittihad claims top spot in Saudi Pro League after victory over Al Fateh    Do cigarettes belong in a museum?    Saudi Arabia joins international partnership initiative to boost hydrogen economy    Riyadh Emir inaugurates International Conference on Conjoined Twins in Riyadh    Saudi Arabia to host 28th Annual World Investment Conference in Riyadh    Saudi Arabia allows licensed flour milling companies to export flour    Katy Perry v Katie Perry: Singer wins right to use name in Australia    Order vs. Morality: Lessons from New York's 1977 Blackout    India puts blockbuster Pakistani film on hold    The Vikings and the Islamic world    Filipino pilgrim's incredible evolution from an enemy of Islam to its staunch advocate    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Single-shot Johnson & Johnson vaccine 66% percent effective
Published in The Saudi Gazette on 29 - 01 - 2021

Johnson & Johnson's COVID-19 single-shot vaccine was shown to be 66 percent effective in preventing moderate and severe disease in a global Phase 3 trial, but 85 percent efficacy against severe disease, the company announced on Friday.
The vaccine was 72 percent effective against moderate and severe disease in the US, the company said.
It's a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one. The vaccines already on the market in the US are about 95 percent effective overall against symptomatic COVID-19, with perhaps even higher efficacy against severe cases.
But experts say the Johnson & Johnson vaccine will still be useful against the pandemic in the United States and around the world.
"Among all participants from different geographies and including those infected with an emerging viral variant, Janssen's COVID-19 vaccine candidate was 66 percent effective overall at preventing the combined endpoints of moderate and severe COVID-19, 28 days after vaccination.
The onset of protection was observed as early as day 14," the company said in a statement.
Janssen is Johnson & Johnson's vaccine arm.
"The level of protection against moderate and severe COVID-19 infection was 72 percent in the US, 66 percent in Latin America and 57 percent in South Africa, 28 days post-vaccination."
"We're 85 percent effective at preventing severe disease, which we define as the disease that makes you feel particularly sick at home, or may go to the hospital, or worse," Dr. Mathai Mammen, global head of research and development at Johnson & Johnson, said.
"And we are right now completely protective, it would appear 100 percent protective, against the disease that actually does make you go to the hospital, we're 100% protective against death."
The company said the results held up across all age groups and people of various ethnicities.
Mammen said the company was working to file for emergency use authorization from the US Food and Drug Administration "inside of a week." It will be the third company to seek EUA from the FDA for a coronavirus vaccine. Vaccines made by Moderna and by Pfizer/BioNTech were authorized in December and are now being given to millions of Americans.
Dr. Paul Offit, a vaccine expert at the University of Pennsylvania and a member of the FDA's Vaccines and Related Biological Products Advisory Committee, said that under normal circumstances, there might not be much of a market for a vaccine that is significantly less effective than two others already on the market. But he added that these are not normal times, with a pandemic raging and a shortage of vaccines.
Pfizer and Moderna both use genetic technology called messenger RNA, or mRNA technology. Johnson & Johnson uses a weakened common cold virus, known as adenovirus, to carry genetic instructions into the body to prompt an immune response.
"In a better world, we would have abundant quantities of this messenger RNA vaccine, Pfizer and Moderna, and that would be damning for a vaccine that's clearly less effective. But that said, we have limited quantities of mRNA vaccine," Offit said.
Unlike the Pfizer and Moderna vaccines, Johnson & Johnson vaccine does not have to be stored in freezers. It can be stored for three months at refrigerator temperatures of 36 degrees to 46 degrees Fahrenheit.
Janssen is already testing a two-dose regimen of the vaccine and that could increase the efficacy.
The US federal government has contracted to buy 100 million doses of the vaccine and the company has been manufacturing doses for months in anticipation that it would work and would win EUA from the FDA.
A fourth vaccine is also jostling to join the mix in the US market. Maryland-based Novavax released preliminary data on Thursday showing its candidate vaccine had an efficacy of 89 percent in trials in Britain. And AstraZeneca is finishing up Phase 3 clinical trials of its vaccine, as well.
The Janssen vaccine is made a little differently from the Pfizer and Moderna vaccines, which use raw genetic material called messenger RNA. — Courtesy CNN


Clic here to read the story from its source.